Avutometinib/Defactinib May be a New SOC in Low-Grade Serous Ovarian Cancer
Interim data reveal favorable responses in patients with low-grade serous ovarian cancer treated with avutometinib plus defactinib, according to Susana N. Banerjee, MD.